Day: November 21, 2022

Ye, Bihai published the artcileRhodium-Catalyzed Asymmetric Conjugate Pyridylation with Pyridylboronic Acids, Quality Control of 371766-08-4, the publication is ACS Catalysis (2022), 12(4), 2434-2440, database is CAplus.

In this study, the rhodium-catalyzed asym. conjugate pyridylation of α,β-unsaturated carbonyl compounds with pyridylboronic acids was reported. The bifunctional chiral amide-diene ligand, which dramatically accelerated the reaction via possible H-bonding activation, and alc. solvent, which significantly inhibited the competing protodeboronation of pyridylboronic acids under rhodium catalysis, worked in concert to promote the reaction, thus enabling production of the pyridylation products in high yields (up to 99%) with good enantioselectivities (up to >99% ee).

ACS Catalysis published new progress about 371766-08-4. 371766-08-4 belongs to isoquinoline, auxiliary class Isoquinoline,Boronic acid and ester,Boronic Acids,Boronic acid and ester, name is Isoquinolin-5-ylboronic acid, and the molecular formula is C11H15NO2, Quality Control of 371766-08-4.

Referemce:
https://en.wikipedia.org/wiki/Isoquinoline,
Isoquinoline | C9H7N – PubChem

Carpenter, Joseph published the artcileUtilization of an Active Site Mutant Receptor for the Identification of Potent and Selective Atypical 5-HT_2C Receptor Agonists, Synthetic Route of 371766-08-4, the publication is Journal of Medicinal Chemistry (2017), 60(14), 6166-6190, database is CAplus and MEDLINE.

Agonism of the 5-HT_2C receptor represents one of the most well-studied and clin. proven mechanisms for pharmacol. weight reduction Selectivity over the closely related 5-HT_2A and 5-HT_2B receptors is critical as their activation has been shown to lead to undesirable side effects and major safety concerns. In this communication, we report the development of a new screening paradigm that utilizes an active site mutant D134A (D3.32) 5-HT_2C receptor to identify atypical agonist structures. We addnl. report the discovery and optimization of a novel class of nonbasic heterocyclic amide agonists of 5-HT_2C. SAR investigations around the screening hits provided a diverse set of potent agonists at 5-HT_2C with high selectivity over the related 5-HT_2A and 5-HT_2B receptor subtypes. Further optimization through replacement of the amide with a variety of five- and six-membered heterocycles led to the identification of 6-(1-ethyl-3-(quinolin-8-yl)-1H-pyrazol-5-yl)pyridazin-3-amine (69). Oral administration of 69 to rats reduced food intake in an ad libitum feeding model, which could be completely reversed by a selective 5-HT_2C antagonist.

Journal of Medicinal Chemistry published new progress about 371766-08-4. 371766-08-4 belongs to isoquinoline, auxiliary class Isoquinoline,Boronic acid and ester,Boronic Acids,Boronic acid and ester, name is Isoquinolin-5-ylboronic acid, and the molecular formula is C9H8BNO2, Synthetic Route of 371766-08-4.

Referemce:
https://en.wikipedia.org/wiki/Isoquinoline,
Isoquinoline | C9H7N – PubChem

Paulsen, Janet L. published the artcileStructural analysis of the active sites of dihydrofolate reductase from two species of Candida uncovers ligand-induced conformational changes shared among species, HPLC of Formula: 371766-08-4, the publication is Bioorganic & Medicinal Chemistry Letters (2013), 23(5), 1279-1284, database is CAplus and MEDLINE.

A novel strategy for targeting the pathogenic organisms Candida albicans and Candida glabrata focuses on the development of potent and selective antifolates effective against dihydrofolate reductase. Crystal structure anal. suggested that an essential loop at the active site (Thr 58-Phe 66) differs from the analogous residues in the human enzyme, potentially providing a mechanism for achieving selectivity. In order to probe the role of this loop, we employed chem. synthesis, crystal structure determination and mol. dynamics simulations. The results of these analyses show that the loop residues undergo ligand-induced conformational changes that are similar among the fungal and human species.

Bioorganic & Medicinal Chemistry Letters published new progress about 371766-08-4. 371766-08-4 belongs to isoquinoline, auxiliary class Isoquinoline,Boronic acid and ester,Boronic Acids,Boronic acid and ester, name is Isoquinolin-5-ylboronic acid, and the molecular formula is C9H8BNO2, HPLC of Formula: 371766-08-4.

Referemce:
https://en.wikipedia.org/wiki/Isoquinoline,
Isoquinoline | C9H7N – PubChem

Yu, Mingfeng published the artcilePotent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation, HPLC of Formula: 371766-08-4, the publication is European Journal of Medicinal Chemistry (2021), 113248, database is CAplus and MEDLINE.

CDK8 regulates transcription either by phosphorylation of transcription factors or, as part of a four-subunit kinase module, through a reversible association of the kinase module with the Mediator complex, a highly conserved transcriptional coactivator. Deregulation of CDK8 has been found in various types of human cancer, while the role of CDK8 in suppressing anti-cancer response of natural killer cells is being understood. Currently, CDK8-targeting cancer drugs are highly sought-after. Herein authors detail the discovery of a series of novel pyridine-derived CDK8 inhibitors. Medicinal chem. optimization gave rise to I (AU1-100), a potent CDK8 inhibitor with oral bioavailability. The compound inhibited the proliferation of MV4-11 acute myeloid leukemia cells with the kinase activity of cellular CDK8 dampened. No systemic toxicol. was observed in the mice treated with I. These results warrant further pre-clin. studies of I as an anti-cancer agent.

European Journal of Medicinal Chemistry published new progress about 371766-08-4. 371766-08-4 belongs to isoquinoline, auxiliary class Isoquinoline,Boronic acid and ester,Boronic Acids,Boronic acid and ester, name is Isoquinolin-5-ylboronic acid, and the molecular formula is C5H5BrN2, HPLC of Formula: 371766-08-4.

Referemce:
https://en.wikipedia.org/wiki/Isoquinoline,
Isoquinoline | C9H7N – PubChem

Cox, Robert M. published the artcileOrally efficacious broad-spectrum allosteric inhibitor of paramyxovirus polymerase, Recommanded Product: Isoquinolin-5-ylboronic acid, the publication is Nature Microbiology (2020), 5(10), 1232-1246, database is CAplus and MEDLINE.

In a high-throughput screen for inhibitors of HPIV3 (a major cause of acute respiratory infection), we identified GHP-88309-a non-nucleoside inhibitor of viral polymerase activity that possesses unusual broad-spectrum activity against diverse paramyxoviruses including respiroviruses (i.e., HPIV1 and HPIV3) and morbilliviruses (i.e., MeV). Resistance profiles of distinct target viruses overlapped spatially, revealing a conserved binding site in the central cavity of the viral polymerase (L) protein that was validated by photoaffinity labeling-based target mapping. Mechanistic characterization through viral RNA profiling and in vitro MeV polymerase assays identified a block in the initiation phase of the viral polymerase. GHP-88309 showed nanomolar potency against HPIV3 isolates in well-differentiated human airway organoid cultures, was well tolerated (selectivity index > 7,111) and orally bioavailable, and provided complete protection against lethal infection in a Sendai virus mouse surrogate model of human HPIV3 disease when administered therapeutically 48 h after infection. Recoverees had acquired robust immunoprotection against reinfection, and viral resistance coincided with severe attenuation. This study provides proof of the feasibility of a well-behaved broad-spectrum allosteric antiviral and describes a chemotype with high therapeutic potential that addresses major obstacles of anti-paramyxovirus drug development.

Nature Microbiology published new progress about 371766-08-4. 371766-08-4 belongs to isoquinoline, auxiliary class Isoquinoline,Boronic acid and ester,Boronic Acids,Boronic acid and ester, name is Isoquinolin-5-ylboronic acid, and the molecular formula is C9H8BNO2, Recommanded Product: Isoquinolin-5-ylboronic acid.

Referemce:
https://en.wikipedia.org/wiki/Isoquinoline,
Isoquinoline | C9H7N – PubChem

Wiles, Jason A. published the artcileBiological evaluation of isothiazoloquinolones containing aromatic heterocycles at the 7-position: In vitro activity of a series of potent antibacterial agents that are effective against methicillin-resistant Staphylococcus aureus, Recommanded Product: Isoquinolin-5-ylboronic acid, the publication is Bioorganic & Medicinal Chemistry Letters (2006), 16(5), 1277-1281, database is CAplus and MEDLINE.

A diverse series of 9H-isothiazolo[5,4-b]quinoline-3,4-diones containing heteroaromatic groups at the 7-position was prepared via palladium-catalyzed cross-coupling. Many of these compounds demonstrated potent antistaphylococcal activity (MICs â‰? μg/mL) against a multi-drug-resistant strain (ATCC 700699) and low cytotoxic activity (CC₅₀ > 100 μM) against the human cell line Hep2 (laryngeal carcinoma).

Bioorganic & Medicinal Chemistry Letters published new progress about 371766-08-4. 371766-08-4 belongs to isoquinoline, auxiliary class Isoquinoline,Boronic acid and ester,Boronic Acids,Boronic acid and ester, name is Isoquinolin-5-ylboronic acid, and the molecular formula is C16H18O4, Recommanded Product: Isoquinolin-5-ylboronic acid.

Referemce:
https://en.wikipedia.org/wiki/Isoquinoline,
Isoquinoline | C9H7N – PubChem

Kekesi, Laszlo published the artcileSynthesis and biological evaluation of novel pyrido[2,3-b]pyrazines inhibiting both erlotinib-sensitive and erlotinib-resistant cell lines, SDS of cas: 371766-08-4, the publication is Bioorganic & Medicinal Chemistry Letters (2013), 23(22), 6152-6155, database is CAplus and MEDLINE.

A series of novel pyrido[2,3-b]pyrazines I [R¹ = H, Ph, 4-MeC₆H₄, etc.; R² = H, Ph, 2-thienyl, etc.; R³ = pyridin-3-yl, quinolin-3-yl; indol-4-yl, etc.] were synthesized as potential antitumor agents for erlotinib-resistant tumors. Known signal inhibitor compounds from the Nested Chem. Library were tested in phenotypic assays on erlotinib-sensitive PC9 and erlotinib-resistant PC9-ER cell lines to find a compound class to be active on erlotinib resistant cell lines. Based on the screening data, novel pyrido[2,3-b]pyrazines were designed and synthesized. The effect of the substituent position of the heteroaromatic moiety in position 7 and the importance of unsubstituted position 2 of the pyridopyrazine core were explored. Compound I [R¹R² = 1,4-benzodioxan-6-yl; R³ = indol-5-yl] had an IC₅₀ value of 0.09 μM for the inhibition of PC9 and 0.15 μM for the inhibition of PC9-ER. The authors found that some lead compounds of these structures overcome erlotinib-resistance which might become promising drug candidates to fight against NSCLC with EGFR T790M mutation. The signaling network(s) involved in the mechanism(s) of action of these novel compounds in overcoming erlotinib resistance remain to be elucidated.

Bioorganic & Medicinal Chemistry Letters published new progress about 371766-08-4. 371766-08-4 belongs to isoquinoline, auxiliary class Isoquinoline,Boronic acid and ester,Boronic Acids,Boronic acid and ester, name is Isoquinolin-5-ylboronic acid, and the molecular formula is C9H8BNO2, SDS of cas: 371766-08-4.

Referemce:
https://en.wikipedia.org/wiki/Isoquinoline,
Isoquinoline | C9H7N – PubChem

Wrzeszcz, Zuzanna published the artcileHeteroaromatic N-oxides modified with a chiral oxazoline moiety, synthesis and catalytic applications, Formula: C18H14N2O, the publication is Catalysts (2021), 11(4), 444, database is CAplus.

A multi-step synthesis of a series of chiral oxazoline substituted pyridine N-oxides I (R¹ = i-pr, t-bu, Ph; R² = H; R¹ = R² = indane, trimethyl-bicyclo[2.2.1]heptane), alkyl derived of pyridine N-oxides II, bipyridine N-oxides III, and isoquinoline N-oxides IV, based on amino alcs. R¹(NH2)HC-CH(OH)R² derived from natural amino acids or other previously prepared, is presented herein. Various synthetic pathways have been designed and tested according to the properties and limitations imposed by the target products. The encountered problems related to the stability of the products were discussed. The resulting compounds (eighteen structures) were tested as catalysts in the allylation of benzaldehyde (obtaining up to 79% ee) as well as in nitroaldol reaction (obtaining up to 48% ee).

Catalysts published new progress about 2058236-53-4. 2058236-53-4 belongs to isoquinoline, auxiliary class Mono-oxazoline Ligands, name is (S)-2-(Isoquinolin-1-yl)-4-phenyl-4,5-dihydrooxazole, and the molecular formula is C15H12O8, Formula: C18H14N2O.

Referemce:
https://en.wikipedia.org/wiki/Isoquinoline,
Isoquinoline | C9H7N – PubChem

Gesmundo, Nathan J. published the artcileNanoscale synthesis and affinity ranking, Product Details of C9H8BNO2, the publication is Nature (London, United Kingdom) (2018), 557(7704), 228-232, database is CAplus and MEDLINE.

Most drugs are developed through iterative rounds of chem. synthesis and biochem. testing to optimize the affinity of a particular compound for a protein target of therapeutic interest. This process is challenging because candidate mols. must be selected from a chem. space of more than 10⁶⁰ drug-like possibilities¹, and a single reaction used to synthesize each mol. has more than 10⁷ plausible permutations of catalysts, ligands, additives and other parameters². The merger of a method for high-throughput chem. synthesis with a biochem. assay would facilitate the exploration of this enormous search space and streamline the hunt for new drugs and chem. probes. Miniaturized high-throughput chem. synthesis^3-7 has enabled rapid evaluation of reaction space, but so far the merger of such syntheses with bioassays has been achieved with only low-d. reaction arrays, which analyze only a handful of analogs prepared under a single reaction condition^8-13. High-d. chem. synthesis approaches that have been coupled to bioassays, including on-bead¹⁴, on-surface¹⁵, on-DNA¹⁶ and mass-encoding technologies¹⁷, greatly reduce material requirements, but they require the covalent linkage of substrates to a potentially reactive support, must be performed under high dilution and must operate in a mixture format. These reaction attributes limit the application of transition-metal catalysts, which are easily poisoned by the many functional groups present in a complex mixture, and of transformations for which the kinetics require a high concentration of reactant. Here the authors couple high-throughput nanomole-scale synthesis with a label-free affinity-selection mass spectrometry bioassay. Each reaction is performed at a 0.1-M concentration in a discrete well to enable transition-metal catalysis while consuming less than 0.05 mg of substrate per reaction. The affinity-selection mass spectrometry bioassay is then used to rank the affinity of the reaction products to target proteins, removing the need for time-intensive reaction purification This method enables the primary synthesis and testing steps that are critical to the invention of protein inhibitors to be performed rapidly and with minimal consumption of starting materials.

Nature (London, United Kingdom) published new progress about 371766-08-4. 371766-08-4 belongs to isoquinoline, auxiliary class Isoquinoline,Boronic acid and ester,Boronic Acids,Boronic acid and ester, name is Isoquinolin-5-ylboronic acid, and the molecular formula is C9H8BNO2, Product Details of C9H8BNO2.

Referemce:
https://en.wikipedia.org/wiki/Isoquinoline,
Isoquinoline | C9H7N – PubChem

Berlot, Jean published the artcileAminoquinolines. XI. Decomposition of tertiary 4-aminoquinolines and of related amines by hydrobromic acid in aqueous solution. Influence of the nature of the ring and of the hydrocarbon chain, Formula: C10H10N2, the publication is Bulletin de la Societe Chimique de France (1973), 3175-8, database is CAplus.

Tertiary 4-aminoquinolines I [R = R1 = Me, Pr, allyl, Ph, CH2Ph, (CH2)2Ph, (CH2)3Ph; R2 = Me, R3 = H; R-R3 = Me; R = R1 = Pr, R2 = R3 = Me; R = R1 = Me, CH2Ph, R2 = R3 = H] were completely dealkylated to the corresponding secondary amines by boiling dilute HBr. When R �R1 the shorter radical was eliminated preferentially. The reaction was general for N-heterocyclic amines in which the amine was ortho or para to the ring N. Other amines R4NR5R6 (R4 = 2-quinolyl, 3-quinolyl, 5-quinolyl, 4-pyridyl, 1-naphthyl, 2-naphthyl, CH2Ph, Ph) were not dealkylated when R5 = Me and R6 = Me or Ph, but underwent partial dealkylation when R5 = R6 = CH2Ph.

Bulletin de la Societe Chimique de France published new progress about 46000-11-7. 46000-11-7 belongs to isoquinoline, auxiliary class Isoquinoline,Amine, name is N-Methylisoquinolin-1-amine, and the molecular formula is C10H10N2, Formula: C10H10N2.

Referemce:
https://en.wikipedia.org/wiki/Isoquinoline,
Isoquinoline | C9H7N – PubChem